News

1 to 9 of 20 results

Phylogica inks $142 million license deal with Genentech

Phylogica inks $142 million license deal with Genentech

22-12-2014

Australian drug discovery firm Phylogica has extended its collaboration with Genentech, the biotech subsidiary…

Antibiotics and Infectious diseasesAustraliaBiotechnologyGenentechLicensingPhylogicaResearchRoche

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

17-12-2014

Biopharma company Emergent BioSolutions has acquired the EV-035 series of molecules from Evolva Holding.

Antibiotics and Infectious diseasesBiotechnologyEmergent BioSolutionsEvolvaLicensingResearchUSA

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Debiopharm signs deal with Nobelex Biotech over antibiotics

Debiopharm signs deal with Nobelex Biotech over antibiotics

27-06-2014

Swiss pharma company Debiopharm Group and Canadian biotech company Nobelex Biotech have announced a collaboration…

Antibiotics and Infectious diseasesBiotechnologyCanadaDebiopharmLicensingNobelex Biotech

Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25-02-2014

European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Soligenix and Intrexon collaborate on Melioidosis therapy development

01-05-2013

US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

Termination of Shigamabs deal with LFB Biotech leads Thallion to review options

21-02-2013

Canada-based Thallion Pharmaceuticals (TSX VENTURE: TLN) and LFB Biotechnologies of France have terminated…

Antibiotics and Infectious diseasesBiotechnologyLFB BiotechnologiesLicensingShigamabsThallion Pharmaceuticals

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

1 to 9 of 20 results

Back to top